The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata

J Am Acad Dermatol. 2001 Jan;44(1):73-6. doi: 10.1067/mjd.2001.109309.

Abstract

Background: Highly variable results of topical diphenylcyclopropenone (DPCP) in the treatment of alopecia areata have been reported so far.

Objective: The purposes of our study were to evaluate the efficacy and tolerability of DPCP in the treatment of chronic, extensive alopecia areata and to assess the long-term overall benefit of treatment.

Methods: Fifty-six patients with chronic, extensive alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2% DPCP, progressively higher concentrations beginning at 0.001% were applied weekly for 6 to 12 months to one side of the scalp.

Results: Fifty-two of 56 patients completed therapy. Total regrowth of terminal hair was achieved in 25 of 52 patients (48%) at 6 months. The most frequent side effect was an eczematous reaction at the site of application. Notably, persistent response was observed in 60% of these patients after 6 to 18 months of follow-up (mean, 12 months).

Conclusion: Topical DPCP treatment for alopecia areata is effective and well tolerated and provides prolonged therapeutic benefits.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Alopecia Areata / drug therapy*
  • Chronic Disease
  • Cyclopropanes / administration & dosage*
  • Cyclopropanes / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Cyclopropanes
  • diphenylcyclopropenone